Eledon Pharmaceuticals (ELDN)
NASDAQ:ELDN
Total Valuation
Eledon Pharmaceuticals has a market cap or net worth of $233.62M. The enterprise value is $162.48M.
Market Cap$233.62M
Enterprise Value$162.48M
Share Statistics
Eledon Pharmaceuticals has 75,851,720 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding75,851,720
Owned by Insiders0.03%
Owned by Institutions33.66%
Financial Efficiency
Eledon Pharmaceuticals’s return on equity (ROE) is -0.33 and return on invested capital (ROIC) is -37.91%.
Return on Equity (ROE)-0.33
Return on Assets (ROA)-0.19
Return on Invested Capital (ROIC)-37.91%
Return on Capital Employed (ROCE)-0.38
Revenue Per Employee0.00
Profits Per Employee-1.47M
Employee Count31
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Eledon Pharmaceuticals is ―. Eledon Pharmaceuticals’s PEG ratio is 0.11.
PE Ratio―
PS Ratio0.00
PB Ratio0.90
Price to Fair Value0.90
Price to FCF-1.98
Price to Operating Cash Flow-3.73
PEG Ratio0.11
Income Statement
In the last 12 months, Eledon Pharmaceuticals had revenue of 0.00 and earned -45.62M in profits. Earnings per share was -0.56.
Revenue0.00
Gross Profit0.00
Operating Income-83.25M
Pretax Income-45.58M
Net Income-45.62M
EBITDA-83.25M
Earnings Per Share (EPS)-0.56
Cash Flow
In the last 12 months, operating cash flow was -62.34M and capital expenditures 0.00, giving a free cash flow of -62.34M billion.
Operating Cash Flow-62.34M
Free Cash Flow-62.34M
Free Cash Flow per Share-0.82
Dividends & Yields
Eledon Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.20
52-Week Price Change-4.35%
50-Day Moving Average2.45
200-Day Moving Average2.57
Relative Strength Index (RSI)50.44
Average Volume (3m)1.31M
Important Dates
Eledon Pharmaceuticals upcoming earnings date is May 7, 2026, Before Open (Confirmed).
Last Earnings DateMar 19, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Eledon Pharmaceuticals as a current ratio of 7.40, with Debt / Equity ratio of 0.47%
Current Ratio7.40
Quick Ratio7.40
Debt to Market Cap<0.01
Net Debt to EBITDA0.27
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Eledon Pharmaceuticals has paid 35.00K in taxes.
Income Tax35.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Eledon Pharmaceuticals EV to EBITDA ratio is -1.22, with an EV/FCF ratio of -1.63.
EV to Sales0.00
EV to EBITDA-1.22
EV to Free Cash Flow-1.63
EV to Operating Cash Flow-1.63
Balance Sheet
Eledon Pharmaceuticals has $133.34M in cash and marketable securities with $641.00K in debt, giving a net cash position of $132.69M billion.
Cash & Marketable Securities$133.34M
Total Debt$641.00K
Net Cash$132.69M
Net Cash Per Share$1.75
Tangible Book Value Per Share$1.28
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Eledon Pharmaceuticals is $7.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$7.33
Price Target Upside170.48% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast72.35%